leadXpro produces protein for COVID-19 research campaign
Villigen, Switzerland, May 19th, 2020 – leadXpro AG, a structure-based drug discovery company today announced its involvement in a multiparty research collaboration and delivery of the SARS-CoV-2 M-glycoprotein, a promising therapeutic target against Covid-19.
The COVID-19 pandemic has galvanized scientists around the world to find innovative new therapies to fight the disease. leadXpro has joined forces with a network of Swiss academic and industrial collaborators, including PSI, ETH Zürich, Creoptix AG and many others, to contribute to research efforts coordinated by the Swiss National COVID-19 Science Task Force.
One key viral target is the Covid-19 M-protein, a surface protein critical for viral capsid assembly. leadXpro has developed a method to produce this membrane protein in a purified, crystallization-grade form, drawing on its deep expertise in working with challenging membrane proteins for pharmaceutical study. The protein represents an essential research tool and its high quality ensures successful application in research projects. Interested parties wishing to receive protein are invited to contact the company using the e-mail address info@leadXpro.com or any other media channel.
Dr Mathieu Botte, Senior Scientist at leadXpro leading the project, commented “In these challenging times, we are grateful to be in a position to utilize our resources and capabilities to contribute to the global fight against COVID-19. We look forward to working closely with our collaborators to see results that contribute scientifically to a better understanding of the disease, as well as discovery of novel therapeutics.”
About leadXpro AG
leadXpro AG is a lead discovery company focusing on membrane protein drug targets. We are committed to the application of biophysical and structure-based methods for the discovery and optimization of next generation lead compounds. leadXpro’s technology platform enables structural determination of membrane proteins unlocking structure-based drug discovery for challenging targets. We capitalize on access to Swiss research facilities such as the synchrotron Swiss Light Source (SLS) and the Free Electron Laser (SwissFEL). Core expertise beyond X-ray includes single particle cryo-electron microscopy (cryo-EM). We also collaborate with industry partners on propriety research, ensuring full confidentiality. For more information, please visit www.leadxpro.com.
leadXpro is a registered trademark in the EU, Switzerland, US and Canada.
leadXpro AG Michael Hennig, CEO michael.hennig@leadXpro.com